Treatment for Caffeine Dependence
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | September 2013 |
| End Date: | March 2017 |
| Contact: | Mary M Sweeney, PhD |
| Email: | msween19@jhmi.edu |
| Phone: | 410-550-3076 |
Recent research has shown that some individuals become addicted to or dependent on caffeine
and are unable to quit or reduce caffeine consumption despite a persistent desire to do so.
The aims of the current study are to characterize caffeine use among individuals with
physical or psychological dependence on caffeine and evaluate a manual-based intervention to
promote caffeine reduction and cessation.
and are unable to quit or reduce caffeine consumption despite a persistent desire to do so.
The aims of the current study are to characterize caffeine use among individuals with
physical or psychological dependence on caffeine and evaluate a manual-based intervention to
promote caffeine reduction and cessation.
A large percentage of caffeine users in the general population (56%) report a persistent
desire or unsuccessful efforts to stop or reduce caffeine consumption. The aim of Study 1 is
to recruit and identify individuals who are interested in receiving treatment to reduce or
quit caffeine consumption. Individuals will be recruited from Baltimore, MD and surrounding
communities via flyers and newspaper and radio advertisements. Those who are eligible will
be invited to come to the Behavioral Pharmacology Research Unit located on the Johns Hopkins
Bayview Medical Center campus in Baltimore, MD. After consent is obtained at intake (consent
form A), a series of questionnaires will be completed (e.g., demographics, caffeine history,
medical and psychiatric history, mood), followed by a structured clinical interview that
will assess caffeine use and dependence. Individuals who meet eligibility criteria will be
offered the opportunity to receive assistance to reduce or quit caffeine. Those who consent
(consent form B) to enroll in the second phase of the project will be randomly assigned to
one of two conditions: 1) immediate treatment or 2) delayed treatment. The conditions will
be identical with the exception of a 6 week delay for the delayed treatment group.
Participants will receive a caffeine reduction and cessation treatment manual during a brief
treatment session at week 1. Treatment progress will be assessed during a study session
approximately 7 weeks post-treatment, during a telephone interview approximately 8 weeks
post-treatment, and during a follow-up telephone call approximately 27 weeks after the
treatment session. Progress will be assessed via questionnaires, food diaries, and salivary
caffeine measures.
desire or unsuccessful efforts to stop or reduce caffeine consumption. The aim of Study 1 is
to recruit and identify individuals who are interested in receiving treatment to reduce or
quit caffeine consumption. Individuals will be recruited from Baltimore, MD and surrounding
communities via flyers and newspaper and radio advertisements. Those who are eligible will
be invited to come to the Behavioral Pharmacology Research Unit located on the Johns Hopkins
Bayview Medical Center campus in Baltimore, MD. After consent is obtained at intake (consent
form A), a series of questionnaires will be completed (e.g., demographics, caffeine history,
medical and psychiatric history, mood), followed by a structured clinical interview that
will assess caffeine use and dependence. Individuals who meet eligibility criteria will be
offered the opportunity to receive assistance to reduce or quit caffeine. Those who consent
(consent form B) to enroll in the second phase of the project will be randomly assigned to
one of two conditions: 1) immediate treatment or 2) delayed treatment. The conditions will
be identical with the exception of a 6 week delay for the delayed treatment group.
Participants will receive a caffeine reduction and cessation treatment manual during a brief
treatment session at week 1. Treatment progress will be assessed during a study session
approximately 7 weeks post-treatment, during a telephone interview approximately 8 weeks
post-treatment, and during a follow-up telephone call approximately 27 weeks after the
treatment session. Progress will be assessed via questionnaires, food diaries, and salivary
caffeine measures.
Inclusion Criteria:
- Medically healthy
- Self-reported problem with caffeine use
- Moderate to heavy caffeine use
Exclusion Criteria:
- Pregnancy
- Current dependence on alcohol or illicit drugs
We found this trial at
1
site
Baltimore, Maryland 21224
Principal Investigator: Roland R Griffiths, PhD
Phone: 410-550-3076
Click here to add this to my saved trials
